A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | MicrobiomeTrials
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-05-08Est. Completion: 2040-06-01
Enrollment target: 60 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States